Levosimendan in patients with acute myocardial ischaemia undergoing emergency surgical revascularization

European Journal of Anaesthesiology

Volumn 25, Issue 3, 2008, Pages 224-229

  Lehmann, A ^a   Kiessling, A H ^a   Isgro, F ^a   Zeitler, C ^a   Thaler, E ^a   Boldt, J ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

Author keywords

Coronary artery bypass; Ischaemia reperfusion injury, heart; Myocardial ischaemia; Simendan, levosimendan

Indexed keywords

ADRENALIN; CATECHOLAMINE DERIVATIVE; DOBUTAMINE; LEVOSIMENDAN; NORADRENALIN;

ADULT; AGED; AORTA BALLOON; ARTICLE; ARTIFICIAL VENTILATION; CARDIOGENIC SHOCK; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; EMERGENCY SURGERY; FEMALE; HEART HEMODYNAMICS; HEART INDEX; HEART MUSCLE ISCHEMIA; HUMAN; HYPOTENSION; MALE; MORTALITY; REVASCULARIZATION; SYSTOLIC BLOOD PRESSURE;

ACUTE DISEASE; AGED; ANTI-ARRHYTHMIA AGENTS; BLOOD PRESSURE; CASE-CONTROL STUDIES; CATECHOLAMINES; COHORT STUDIES; CORONARY ARTERY BYPASS; EMERGENCIES; FEMALE; HEART RATE; HUMANS; HYDRAZONES; INFUSIONS, INTRAVENOUS; INTRA-AORTIC BALLOON PUMPING; LENGTH OF STAY; MALE; MIDDLE AGED; MONITORING, INTRAOPERATIVE; MYOCARDIAL ISCHEMIA; MYOCARDIAL REVASCULARIZATION; PYRIDAZINES; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES; SHOCK, CARDIOGENIC; SURVIVAL RATE; VASCULAR RESISTANCE;

EID: 38649116373     PISSN: 02650215     EISSN: 13652346     Source Type: Journal    
DOI: 10.1017/S0265021507002761     Document Type: Article

References (29)

1. Khoynezhad A, Jalali Z, Tortolani AJ. Apoptosis: pathophysiology and therapeutic implications for the cardiac surgeon. Ann Thorac Surg 2004; 78: 1109-1118.
2. Lagerqvist B, Husted S, Kotny F et al. Fast Revascularistaion during InStability in Coronary artery disease (FRISC-II) investigators. 5-year outcomes in the FRISC-II randomised trial of an invasive vs. a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study. Lancet 2006; 368: 998-1004.
3. Fox KA, Poole-Wilson P, Clayton TC et al. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. Lancet 2005; 366: 914-920.
4. Acute Coronary Syndrome Guidelines Working Group. Guidelines for the management of acute coronary syndromes 2006. Med J Aust 2006; 184(Suppl 8): S1-S32.
5. Maytin M, Colucci WS. Cardioprotection: a new paradigm in the management of acute heart failure syndromes. Am J Cardiol 2005; 96: 26G-31G.
6. Haikala H, Pollesello P. Calcium sensitivity enhancers. Idrugs 2000; 3: 1199-1205.
7. Sorsa T, Heikkinen S, Abbott MB et al. Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. J Biol Chem 2001; 276: 9337-9343.
8. ATP channels. Anesth Analg 2000; 90: 5-11.
9. ATP channels are upstream and p38MAPK is downstream of PKC. BMC Physiol 2002; 2: 10.
10. Roques F, Nashef SA, Michel P et al. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg 1999; 15: 816-822.
11. Roques F, Michel P, Goldstone AR, Nashef SA. The logistic EuroSCORE. Eur Heart J 2003; 24: 881-882.
12. Hochman JS, Sleeper LA, Webb JG et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med 1999; 341: 625-634.
13. Ducas J, Grech ED. ABC of interventional cardiology. Percutaneous coronary intervention: cardiogenic shock. BMJ 2003; 326: 1450-1452.
14. Lehmann A, Lang J, Boldt J, Isgro F, Kiessling AH. Levosimendan in patients with cardiogenic shock undergoing surgical revascularization: a case series. Med Sci Monit 2004; 10: MT89-MT93.
15. Pinto DS, Kirtane AJ, Nallamothu BK et al. Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation 2006; 114: 2019-2025.
16. Le May MR, Davies RF, Dionne R et al. Comparison of early mortality of paramedic-diagnosed ST-segment elevation myocardial infarction with immediate transport to a designated primary percutaneous coronary intervention center to that of similar patients transported to the nearest hospital. Am J Cardiol 2006; 98: 1329-1333.
17. Berger PB, Ellis SG, Holmes Jr. DR et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in acute coronary syndromes (GUSTO-IIb) trial. Circulation 1999; 100: 14-20.
18. Bassand JP, Danchin N, Filippatos G et al. Implementation of reperfusion therapy in acute myocardial infarction. A policy statement from the European Society of Cardiology. Eur Heart J 2005; 26: 2733-2741.
19. Pollesello P, Mebazaa A. ATP-dependent potassium channels as a key target for the treatment of myocardial and vascular dysfunction. Curr Opin Crit Care 2004; 10: 436-441.
20. Sugimoto K, Ito H, Iwakura K et al. Intravenous nicorandil in conjunction with coronary reperfusion therapy is associated with better clinical and functional outcomes in patients with acute myocardial infarction. Circ J 2003; 67: 295-300.
21. Chinnan NK, Puri GD, Thingnam SK. Myocardial protection by nicorandil during open-heart surgery under cardiopulmonary bypass. Eur J Anaesthesiol 2007; 24: 26-32.
22. Toller WG, Stranz C. Levosimendan, a new inotropic and vasodilator agent. Anesthesiology 2006; 104: 556-569.
23. Sonntag S, Sundberg S, Lehtonen LA, Kleber FX. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol 2004; 43: 2177-2182.
24. 2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail 2005; 7: 882-887.
25. Adamopoulos S, Parissis JT, Iliodromitis EK et al. Effects of levosimendan vs. dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol 2006; 98: 102-106.
26. Tritapepe L, De Santis V, Vitale D et al. Preconditioning effects of levosimendan in coronary artery bypass grafting - a pilot study. Br J Anaesth 2006; 96: 694-700.
27. ATP channels in cell survival and death. J Mol Cell Cardiol 2005; 39: 7-16.
28. Zager RA, Johnson AC, Lund S, Hanson SY, Abrass CK. Levosimendan protects against experimental endotoxemic acute renal failure. Am J Physiol Renal Physiol 2006; 290: F1453-F1462.
29. Feneck R. Clinical research in anaesthesia; randomized controlled trials or observational studies. Eur J Anaesthesiol 2007; 24: 1-5.